Pfizer joint ventures with China's Guoyuan on animal vax; Alkermes shareholders OK Elan drug tech deal;

@FiercePharma: Genzyme apologizes for latest Fabrazyme delay. News | Follow @FiercePharma 

> Pfizer ($PFE) has inked a joint-venture deal with China's Guoyuan to develop and sell animal vaccines in that country. More

> Ipca Laboratories, which owns about one-third of Tinora Pharma, is considering merging the latter company into itself. Piece

> Alkermes ($ALKS) shareholders approved its $960 million acquisition of Elan's drug technologies business. Article

> Bristol-Myers Squibb ($BMY) wrapped up its $325 million-plus-milestones acquisition of Amira, which brings a pipeline of anti-inflammatory drugs. BMS release | Report 

> Shire CEO Angus Russell says drugmakers need to pay much closer attention to reimbursement policies and to the comparative data necessary to persuade price-conscious payers to foot the bill for new meds. Story

> Irish distributor Eurodrug was ordered to pay €295,000 in a wrongful dismissal suit filed by its former managing director, Michael Fitzpatrick. Item

> A federal appeals court dismissed two lawsuits challenging the 2010 healthcare reform law, adding to the split decisions that will eventually have to be sorted out. News

Biotech News

@FierceBiotech: Big Pharma VCs may complement traditional venture. Story | Follow @FierceBiotech

@JohnCFierce: Crescendo bioscience (diagnostics) gets $56M in venture cash, myriad debt deal tied to buyout option. Item | Follow @JohnCFierce 

@RyanMFierce: Bruce Booth analyzes our shrinking biotech eco system, 27% drop in biopharmas over past 5 years. News | Follow @RyanMFierce

> Analysis: Biotech herd shrinks 27% amid industry upheaval. Item

> J&J's blockbuster hopeful Xarelto bounces back with AdComm backing. News

> GSK's VC unit SR One has new chief. Story

> Dendreon cuts deep into work force to conserve cash. More 

And Finally... Federal regulators have punted on potential limits to prescription drugs found in drinking water. Report

Suggested Articles

Merck's Keytruda has new long-term survival results that the drugmaker hopes will help bolster its position in first-line NSCLC.

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.